Research programme: viral budding inhibitors - Biotron

Drug Profile

Research programme: viral budding inhibitors - Biotron

Alternative Names: BIT 009; Next-generation viroporin inhibitors - Biotron

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotron
  • Developer Biotron; ImQuest BioSciences; National Institutes of Health (USA)
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus p7 protein inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; Human immunodeficiency virus 1 vpu protein inhibitors; SARS coronavirus E protein-inhibitors; Viral protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coronavirus infections; Dengue; Hepatitis C; HIV infections

Highest Development Phases

  • Research Zika virus infection
  • No development reported Coronavirus infections; Dengue; Hepatitis C; HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Australia
  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Australia
  • 04 Nov 2017 No recent reports of development identified for research development in Dengue in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top